title: Presentation of amyloidosis in carriers of the codon 692 mutation in the amyloid precursor protein gene (APP692).
abstract: Several mutations in the amyloid precursor protein (APP) gene may lead to either Alzheimer's disease or cerebral haemorrhage due to congophilic amyloid angiopathy (CAA). A single family is known in which both types of pathology are expressed because of a missense mutation at codon 692 of the APP gene (APP692). Here we describe the clinical and pathological expression of APP692 in eight patients with the mutation. Furthermore, 21 first-degree relatives with an a priori risk of 50% of being a carrier were tested for the APP692 mutation and studied for presymptomatic signs by neurological examination, neuropsychological testing and brain MRI. Patients with APP692 presented with haemorrhage, dementia or both. The dementia in patients with the APP692 mutation was compatible with Alzheimer's disease both clinically and neuropathologically. Of the 21 healthy relatives at 50% risk, five carried the APP692 mutation. The presymptomatic carriers showed a subtle, non-significant impairment of cognitive function compared with relatives without APP692. A significant increase in the number of periventricular and subcortical white matter lesions at young age was seen in presymptomatic carriers (mean age 26.4 years). The findings of this study suggest that a single (genetic) mechanism may underlie the pathology of Alzheimer's disease and CAA. These diseases are manifested subclinically by white matter pathology. Further insight into the relationship between CAA and Alzheimer's disease may provide clues about the aetiology of Alzheimer's disease.
authors.affiliation: Department of Epidemiology and Biostatistics, Erasmus Medical Centre, Rotterdam, The Netherlands.
authors.forename: G
authors.initials: G
authors.lastname: Roks
authors.forename: F
authors.initials: F
authors.lastname: Van Harskamp
authors.forename: I
authors.initials: I
authors.lastname: De Koning
authors.forename: M
authors.initials: M
authors.lastname: Cruts
authors.forename: C
authors.initials: C
authors.lastname: De Jonghe
authors.forename: S
authors.initials: S
authors.lastname: Kumar-Singh
authors.forename: A
authors.initials: A
authors.lastname: Tibben
authors.forename: H
authors.initials: H
authors.lastname: Tanghe
authors.forename: M F
authors.initials: MF
authors.lastname: Niermeijer
authors.forename: A
authors.initials: A
authors.lastname: Hofman
authors.forename: J C
authors.initials: JC
authors.lastname: Van Swieten
authors.forename: C
authors.initials: C
authors.lastname: Van Broeckhoven
authors.forename: C M
authors.initials: CM
authors.lastname: Van Duijn
mesh_terms: D000328:Adult; D017668:Age of Onset; D000544:Alzheimer Disease / Q000235:genetics* / Q000473:pathology; D016564:Amyloid beta-Protein Precursor / Q000235:genetics*; D000686:Amyloidosis / Q000235:genetics* / Q000473:pathology; D005192:Family Health; D005260:Female; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006801:Humans; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D009483:Neuropsychological Tests; D010375:Pedigree
chemical_list: D016564:Amyloid beta-Protein Precursor